| Company* (Country; Symbol) |
Company* (Country; Symbol) |
Product | Terms/Details (Date) |
|
| |||
Althea |
PowderMed Ltd.* (UK) |
Althea was awarded a contract to produce a plasmid DNA-based vaccine against influenza |
The effort will combine Althea's plasmid DNA production method and PowderMed's PMED non-needle injection method; terms of the contract were not disclosed (6/20) |
Auxilium |
Cobra Biologics Ltd. (UK; AIM:CBF) |
Deal for the manufacture of additional cGMP and BLA batches of Auxilium's AA4500 |
The companies later will discuss a nonex- clusive long-term supply agreement under which Cobra would manufacture the injectable enzyme (7/17) |
VaxGen Inc. |
Celltrion Inc. (South Korea) |
Vaxgen sold about 62% of its 21% stake in the Celltrion manufacturing facility for $79M |
Another $50.3M is expected to be realized in 2006 through the sale of the remaining stake; the shares were purchased by Nexol Co. Ltd. and affiliated companies (6/29) |
|
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; PK = Pink Sheets. | |||
To read more on related topics, click on one of the words below.